Antitumor efficacy of AMD3100 was demonstrated in breast cancer where it blocks CXCL12-induced HER2/neu activation in vitro [125] and inhibits tumor growth in vivo [126]. The gene discussed is ERBB2; the disease is breast carcinoma.